RAS Dialogue
Join the discussion! Post comments, ask questions, and share information with RAS experts. Subscribe to receive notifications when a new RAS Dialogue article is posted.
-
Conversation with Elizabeth Jaffee: An Immuno-Oncology UpdateImmunotherapy is becoming part of the "standard of care" for many cancer patients. Elizabeth Jaffee describes how we got here and where we need to go in the future.
-
A Conversation About RAS DimersData are persuasive that RAS proteins are dimeric in living cells, but monomeric in vitro. Pasi Jänne, Chiara Ambrogio, and Frank McCormick discuss the significance of understanding RAS dimers for finding treatments for RAS cancers.
-
Don't Miss the Connection: The Role of RAF1 and ROKα in RAS-Driven CancersCancer caused by a mutant KRAS gene is dependent on the presence of one of its downstream effectors, RAF1 (aka CRAF), but not on ARAF or BRAF. Kinase-independent interaction of RAF1 with ROKα accounts for at least some of this dependence.
-
Genetic Ablation of KRAS in Pancreas Cancer: When an Essential Oncogene Isn’tOf all cancers, pancreatic cancers are most dependent on mutant KRAS. However, many pancreatic cancer cell lines survive loss of their mutant KRAS genes. The adaptations these lines make provide opportunities for treating these deadly cancers.
-
Glutamine, Cystine, and Cancer SusceptibilitiesThe rapid growth of cancer cells generates increased amounts of toxic reactive oxygen species (ROS). Four recent papers show how understanding how cancers deal with ROS can lead to therapeutic opportunities.